Buy Stocks Easy | About Us
June 24, 2021
Buy Stocks Easy | Online Stocks

ADRO


Buy Aduro Biotech, Inc. Stock (symbol: ADRO) Easy Online

Company Name: Aduro Biotech, Inc.

Symbol: ADRO

Sector: Health Care

Industry: Major Pharmaceuticals

IPO: 2015

ADRO Current Share Price

Today's ADRO ( Aduro Biotech, Inc. ) opening price: $1.0000

Yesterday's ADRO ( Aduro Biotech, Inc. ) closing price: $1.0200

Aduro Biotech, Inc. Stock ( symbol: ADRO ) Price Chart since IPO (2015):

12 Months Aduro Biotech, Inc. Stock ( symbol: ADRO ) Price Chart

Popular Questions about Aduro Biotech, Inc. Public Stock ( ADRO )

A: Aduro Biotech, Inc. stock symbol (also called stock or share ticker) is ADRO

A: Aduro Biotech, Inc. IPO (Initial Public Offering) took place on 2015

A: Aduro Biotech, Inc.'s stock (ADRO symbol) price at ther IPO (initial Public Offering) was $1.0000

Q: Is ADRO stock worth buying at the moment?

A: The ADRO stock performance since 2019 are rather disappointing. If you had bought 1 share of Aduro Biotech, Inc. stock (symbol: ADRO) at the beginning of 2019, at the opening share price of $2.9800, you would be left with exactly $1.0000 - which means a waste of your money and time. - SHOW ONLY IF equal or loose.

Buy Aduro Biotech, Inc. Stock Easy Online

Aduro Biotech, Inc. Stock Ticker Price Chart since IPO:





Aduro Biotech, Inc. Stock Price Yesterday



 


Aduro Biotech, Inc. Stock Price – Last Week




 


Aduro Biotech, Inc. Stock Price – Last Month




 


Aduro Biotech, Inc. Stock Value Chart – 12 Months




            

                

                    

                    
                

                
                
Rate this post

                
            

            
            

             

            

        

    



            



    

        

            

                
 Latest Stock News: 

            

        

        



                            

                    


                        
                            http://www.globenewswire.com/news-release/2019/11/08/1944299/0/en/Aduro-Biotech-Announces-Presentation-of-Results-from-First-in-Human-Phase-1-Study-of-Anti-CD27-Agonist-as-Monotherapy-and-in-Combination-with-Pembrolizumab-in-Patients-with-Advance.html
                            

                                
Aduro Biotech Announces Presentation of Results from First-in-Human Phase 1 Study of Anti-CD27 Agonist as Monotherapy and in Combination with Pembrolizumab in Patients with Advanced Solid Tumors at the Society for Immunotherapy of Cancer 34th Annual Meeti

                                
                                
BERKELEY, Calif., Nov.  08, 2019  (GLOBE NEWSWIRE) -- Aduro Biotech...


                            

                        
                    

                


                            

                    


                        
                            http://www.zacks.com/stock/news/609221/aduro-biotech-adro-reports-q3-loss-tops-revenue-estimates
                            

                                
Aduro Biotech (ADRO) Reports Q3 Loss, Tops Revenue Estimates

                                
                                
Aduro Biotech (ADRO) delivered earnings and revenue surprises of -1...


                            

                        
                    

                


                            

                    


                        
                            http://www.globenewswire.com/news-release/2019/10/02/1924363/0/en/Aduro-Biotech-Announces-Two-Abstracts-Accepted-for-Presentation-at-the-Society-for-Immunotherapy-of-Cancer-34th-Annual-Meeting-SITC-2019.html
                            

                                
Aduro Biotech Announces Two Abstracts Accepted for Presentation at the Society for Immunotherapy of Cancer 34th Annual Meeting (SITC 2019)

                                
                                
BERKELEY, Calif., Oct.  02, 2019  (GLOBE NEWSWIRE) -- Aduro Biotech...


                            

                        
                    

                


                            

                    


                        
                            http://www.globenewswire.com/news-release/2019/09/30/1922868/0/en/Aduro-Biotech-to-Present-at-the-2019-Cantor-Global-Healthcare-Conference.html
                            

                                
Aduro Biotech to Present at the 2019 Cantor Global Healthcare Conference

                                
                                
BERKELEY, Calif., Sept.  30, 2019  (GLOBE NEWSWIRE) -- Aduro Biotec...


                            

                        
                    

                


                            

                    


                        
                            http://www.globenewswire.com/news-release/2019/09/04/1910802/0/en/Aduro-Biotech-Announces-First-Patient-Dosed-in-Phase-2-Study-of-ADU-S100-MIW815-in-Combination-with-KEYTRUDA-pembrolizumab-for-First-Line-Treatment-of-Recurrent-or-Metastatic-Head-.html
                            

                                
Aduro Biotech Announces First Patient Dosed in Phase 2 Study of ADU-S100 (MIW815) in Combination with KEYTRUDA® (pembrolizumab) for First-Line Treatment of Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (HNSCC)

                                
                                
BERKELEY, Calif., Sept.  04, 2019  (GLOBE NEWSWIRE) -- Aduro Biotec...


                            

                        
                    

                


                            

                    


                        
                            http://www.globenewswire.com/news-release/2019/09/03/1910355/0/en/Aduro-Biotech-to-Present-at-the-H-C-Wainwright-21st-Annual-Global-Investment-Conference.html
                            

                                
Aduro Biotech to Present at the H.C. Wainwright 21st Annual Global Investment Conference

                                
                                
BERKELEY, Calif., Sept.  03, 2019  (GLOBE NEWSWIRE) -- Aduro Biotec...


                            

                        
                    

                


                            

                    


                        
                            http://www.zacks.com/stock/news/459136/aduro-adro-earnings-miss-in-q2-revenues-meet-estimates
                            

                                
Aduro (ADRO) Earnings Miss in Q2, Revenues Meet Estimates

                                
                                
Aduro (ADRO) suffers wider-than-expected loss in the second quarter...


                            

                        
                    

                


                            

                    


                        
                            http://www.globenewswire.com/news-release/2019/11/08/1944299/0/en/Aduro-Biotech-Announces-Presentation-of-Results-from-First-in-Human-Phase-1-Study-of-Anti-CD27-Agonist-as-Monotherapy-and-in-Combination-with-Pembrolizumab-in-Patients-with-Advance.html
                            

                                
Aduro Biotech Announces Presentation of Results from First-in-Human Phase 1 Study of Anti-CD27 Agonist as Monotherapy and in Combination with Pembrolizumab in Patients with Advanced Solid Tumors at the Society for Immunotherapy of Cancer 34th Annual Meeti

                                
                                
BERKELEY, Calif., Nov.  08, 2019  (GLOBE NEWSWIRE) -- Aduro Biotech...


                            

                        
                    

                


                            

                    


                        
                            http://www.zacks.com/stock/news/609221/aduro-biotech-adro-reports-q3-loss-tops-revenue-estimates
                            

                                
Aduro Biotech (ADRO) Reports Q3 Loss, Tops Revenue Estimates

                                
                                
Aduro Biotech (ADRO) delivered earnings and revenue surprises of -1...


                            

                        
                    

                


                            

                    


                        
                            http://www.globenewswire.com/news-release/2019/10/02/1924363/0/en/Aduro-Biotech-Announces-Two-Abstracts-Accepted-for-Presentation-at-the-Society-for-Immunotherapy-of-Cancer-34th-Annual-Meeting-SITC-2019.html
                            

                                
Aduro Biotech Announces Two Abstracts Accepted for Presentation at the Society for Immunotherapy of Cancer 34th Annual Meeting (SITC 2019)

                                
                                
BERKELEY, Calif., Oct.  02, 2019  (GLOBE NEWSWIRE) -- Aduro Biotech...


                            

                        
                    

                


                            

                    


                        
                            http://www.globenewswire.com/news-release/2019/09/30/1922868/0/en/Aduro-Biotech-to-Present-at-the-2019-Cantor-Global-Healthcare-Conference.html
                            

                                
Aduro Biotech to Present at the 2019 Cantor Global Healthcare Conference

                                
                                
BERKELEY, Calif., Sept.  30, 2019  (GLOBE NEWSWIRE) -- Aduro Biotec...


                            

                        
                    

                


                            

                    


                        
                            http://www.globenewswire.com/news-release/2019/09/04/1910802/0/en/Aduro-Biotech-Announces-First-Patient-Dosed-in-Phase-2-Study-of-ADU-S100-MIW815-in-Combination-with-KEYTRUDA-pembrolizumab-for-First-Line-Treatment-of-Recurrent-or-Metastatic-Head-.html
                            

                                
Aduro Biotech Announces First Patient Dosed in Phase 2 Study of ADU-S100 (MIW815) in Combination with KEYTRUDA® (pembrolizumab) for First-Line Treatment of Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (HNSCC)

                                
                                
BERKELEY, Calif., Sept.  04, 2019  (GLOBE NEWSWIRE) -- Aduro Biotec...


                            

                        
                    

                


                            

                    


                        
                            http://www.globenewswire.com/news-release/2019/09/03/1910355/0/en/Aduro-Biotech-to-Present-at-the-H-C-Wainwright-21st-Annual-Global-Investment-Conference.html
                            

                                
Aduro Biotech to Present at the H.C. Wainwright 21st Annual Global Investment Conference

                                
                                
BERKELEY, Calif., Sept.  03, 2019  (GLOBE NEWSWIRE) -- Aduro Biotec...


                            

                        
                    

                


                            

                    


                        
                            http://www.zacks.com/stock/news/459136/aduro-adro-earnings-miss-in-q2-revenues-meet-estimates
                            

                                
Aduro (ADRO) Earnings Miss in Q2, Revenues Meet Estimates

                                
                                
Aduro (ADRO) suffers wider-than-expected loss in the second quarter...


                            

                        
                    

                


            
        

    




    
    





	
	  

	  All right reserved Buy Stocks Easy , 2019.